A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19

Med（2022）

引用 13|浏览24

暂无评分

摘要

•Patients with COVID-19-associated ARDS were randomized to receive IV AAT or placebo•Patients receiving IV AAT had decreased IL-6, sTNFR1, and CRP at 1 week•Differential glycosylation of endogenous AAT was preserved in the treatment group•Treatment with IV AAT was safe and well tolerated

查看译文

关键词

coronavirus,COVID-19,alpha-1 antitrypsin,interleukin-6,clinical trial,randomized control trial,inflammation,cytokines,acute respiratory distress syndrome

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要